eprosartan (Rx)Brand and Other Names:Teveten

 
 
 

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

tablet

  • 400mg
  • 600mg
more...

Hypertension

Initial: 600 mg PO qDay, in patients without intravascular volume depletion

Maintenance: 400-800 mg/day PO qDay OR divided q12hr PO (twice daily may improve effect)

See also combo with hydrochlorothiazide (Teveten HCT)

Generally adjust qMonth; more aggressively in high-risk patients

Renal Impairment

Dose adjustment not necessary; carefully monitor patient; not to exceed 600 mg/day

Hepatic Impairment

Dose adjustment not necessary; carefully monitor patient; not to exceed 600 mg/day

Additional Information

Similar dosing has been used in diabetic nephropathy, and CHF

Safety and efficacy not established

Hypertension

Initial: 600 mg PO qDay, in patients without intravascular volume depletion

Maintenance: 400-800 mg/day PO qDay OR divided q12hr PO (twice daily may improve effect)

See also combo with hydrochlorothiazide (Teveten HCT)

Generally adjust qMonth; more aggressively in high-risk patients

Next

Interactions

Interaction Checker

eprosartan and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            1-10%

            Upper respiratory infection (8%)

            Cough (4%)

            Abdominal pain (2%)

            Fatigue (2%)

            Frequency Not Defined

            Facial edema

            Dizziness

            Headache

            Neutropenia

            Back pain

            Myalgia

            Previous
            Next

            Warnings

            Black Box Warnings

            Discontinue as soon as possible when pregnancy is detected; affects renin-angiotensin system causing oligohydramnios, which may result in fetal injury and/or death

            Contraindications

            Hypersensitivity

            Pregnancy (2nd/3rd trimesters): significant risk of fetal/neonatal morbidity and mortality

            Bilateral renal artery stenosis

            Do not coadminister with aliskiren in patients with diabetes

            Cautions

            Angioedema, hypovolemia, hyperkalemia, surgery, and anesthesia

            Discontinue STAT if pregnant: potential risk of congenital malformations (see Contraindications and Black Box Warnings)

            Risk of hypotension, especially if hypovolemic/hyponatremic, or on concomitant diuretics or dialysis

            Dual blockade of the renin angiotensin system with ARBs, ACE inhibitors, or aliskiren associated with increased risk for hypotension, hyperkalemia, and renal function changes (including acute renal failure) compared to monotherapy

            Risk of anaphylactoid reactions and/or angioedema

            Increased risk of renal dysfunction with CHF

            Renal/hepatic impairment

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: C (1st trimester); D (2nd & 3rd trimesters). During the second and third trimesters of pregnancy, these drugs have been associated with fetal injury that includes hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death

            Lactation: excretion in milk unknown/not recommended

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Angiotensin II blocker; displaces angiotensin II from AT1 receptor and may lower blood pressure by antagonizing AT1-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water absorption, and hypertrophic responses

            May induce more complete inhibition of renin-angiotensin system compared with ACE inhibitors; does not affect response to bradykinin

            Inhibits the pressor effects of an angiotensin II infusion in a dose-related manner

            Pharmacokinetics

            Half-Life: 5-9 hr

            Onset: 4 hr

            Peak Plasma Time: 4 hr

            Bioavailability: 13%, food & age increases absorption

            Protein Bound: 98%

            Vd: 3.8 L

            Metabolism: Partially conjugated with glucuronic acid in liver

            Metabolites: Acyl glucuronide metabolite (inactive)

            Excretion: Feces (90%), urine (7%)

            Clearance

            • Total Body: 48.5 L/hr
            • Renal: 39-45 mL/min
            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.